Filtered By:
Specialty: Endocrinology
Condition: Diabetes
Drug: Aspirin

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 16 results found since Jan 2013.

Aspirin Versus Clopidogrel Monotherapy for the Secondary Prevention of Recurrent Cerebrovascular Attack Following Previous Ischemic Stroke in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis
ConclusionClopidogrel monotherapy was neither inferior nor superior to aspirin monotherapy for the secondary prevention of recurrent cerebrovascular attack following previous ischemic stroke in patients with T2DM. Hence, clopidogrel or aspirin monotherapy is equally safe and effective in these patients with T2DM.
Source: Diabetes Therapy - March 26, 2020 Category: Endocrinology Source Type: research

Evaluation of low-dose aspirin for primary prevention of ischemic stroke among patients with diabetes: a retrospective cohort study.
CONCLUSIONS: In this study of patients with diabetes, the use of low-dose aspirin showed an increased risk of hospitalization for ischemic stroke. These results suggest that low-dose aspirin use for the primary prevention of ischemic stroke should be reconsidered in patients with diabetes. PMID: 25733983 [PubMed]
Source: Diabetes Metab - March 6, 2015 Category: Endocrinology Authors: Kim YJ, Choi NK, Kim MS, Lee J, Chang Y, Seong JM, Jung SY, Shin JY, Park JE, Park BJ Tags: Diabetol Metab Syndr Source Type: research

Evaluation of low-dose aspirin for primary prevention of ischemic stroke among patients with diabetes: a retrospective cohort study
Conclusions: In this study of patients with diabetes, the use of low-dose aspirin showed an increased risk of hospitalization for ischemic stroke. These results suggest that low-dose aspirin use for the primary prevention of ischemic stroke should be reconsidered in patients with diabetes.
Source: Diabetology and Metabolic Syndrome - February 15, 2015 Category: Endocrinology Authors: Ye-Jee KimNam-Kyong ChoiMi-Sook KimJoongyub LeeYoosoo ChangJong-Mi SeongSun-Young JungJu-Young ShinJi-Eun ParkByung-Joo Park Source Type: research

Regional, age, and sex differences in baseline characteristics of patients enrolled in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)
ConclusionCV risk factors of TECOS participants are reasonably controlled on average, but differences in CV risk management according to region, sex, and history of prior disease exist. This diversity will enhance generalizability of the trial results.
Source: Diabetes, Obesity and Metabolism - January 20, 2015 Category: Endocrinology Authors: M. A. Bethel, J.B. Green, J. Milton, A. Tajar, S. S. Engel, R. M. Califf, R. R. Holman, Tags: ORIGINAL ARTICLE Source Type: research

Regional, age and sex differences in baseline characteristics of patients enrolled in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)
ConclusionThe CV risk factors of participants in TECOS are reasonably controlled, but differences in CV risk management according to region, sex and history of disease exist. This diversity will enhance the generalizability of the trial results.
Source: Diabetes, Obesity and Metabolism - February 13, 2015 Category: Endocrinology Authors: M. A. Bethel, J. B. Green, J. Milton, A. Tajar, S. S. Engel, R. M. Califf, R. R. Holman, Tags: ORIGINAL ARTICLE Source Type: research

Aspirin for primary prevention of cardiovascular and all‐cause mortality events in diabetes: updated meta‐analysis of randomized controlled trials
ConclusionsThe emerging data do not clearly support guidelines that encourage the use of aspirin for the primary prevention of cardiovascular disease in adults with diabetes who are at increased cardiovascular disease risk.This article is protected by copyright. All rights reserved.
Source: Diabetic Medicine - April 16, 2016 Category: Endocrinology Authors: S. K. Kunutsor, S. Seidu, K. Khunti Tags: Systematic Review or Meta ‐analysis Source Type: research

Aspirin for primary prevention of cardiovascular and all ‐cause mortality events in diabetes: updated meta‐analysis of randomized controlled trials
ConclusionsThe emerging data do not clearly support guidelines that encourage the use of aspirin for the primary prevention of cardiovascular disease in adults with diabetes who are at increased cardiovascular disease risk.
Source: Diabetic Medicine - May 21, 2016 Category: Endocrinology Authors: S. K. Kunutsor, S. Seidu, K. Khunti Tags: Systematic Review or Meta ‐analysis Source Type: research

Blood pressure variability: A new target to slow the progression of vascular damage in type 2 diabetes?
Hypertension is a widely recognized cardiovascular risk factor. Besides the correct measurement of systolic blood pressure (BP), of paramount importance in assessing cardiovascular risk, other BP features have been suggested to play a role; among these, the visit-to-visit BP variability is receiving growing support from the scientific literature. Observational studies link BP variability with carotid artery intima media thickness and atherosclerosis (), and in aging people it worsens cardiovascular prognosis and negatively affects cognitive function (). Post-hoc analyses of large trials, like the United Kingdom Transient I...
Source: Journal of Diabetes and Its Complications - December 6, 2013 Category: Endocrinology Authors: Anna Solini Tags: Editorials Source Type: research

Aspirin for primary prevention of cardiovascular disease in patients with diabetes: a meta-analysis
Cardiovascular disease (CVD) remains a large cause of morbidity and mortality in the United States.[1] Each year over 1.5 million Americans suffer from a CVD event (fatal or non-fatal myocardial infarction (MI) or stroke) and approximately 75% of these are a first event.[1,2] Patients with diabetes have a higher CVD event risk than patients without diabetes, and CVD is the leading cause of morbidity and mortality in patients with diabetes.[3] Historically, in addition to lifestyle modifications and control of diabetes mellitus, hypertension and hypercholesterolemia, aspirin has been widely recommended for the primary preve...
Source: Diabetes Research and Clinical Practice - July 26, 2016 Category: Endocrinology Authors: Lianne A. Kokoska, Sheila M. Wilhelm, Candice L. Garwood, Helen D. Berlie Source Type: research

It's reticulated: the liver at the heart of atherosclerosis
Platelets play a critical role in both the initiation and progression of atherosclerosis, and even more so in the ensuing atherothrombotic complications. Low-dose aspirin remains the mainstay of antiplatelet therapy in high-risk patients by reducing the risk of myocardial ischemia, stroke or death due to cardiovascular disease. However, antiplatelet therapies lose their efficacy in people with diabetes mellitus, increasing the risk of future atherothrombotic events. The molecular mechanisms that promote platelet hyperactivity remain unclear but could be due to glycation-induced conformational changes of platelet membranes ...
Source: Journal of Endocrinology - May 29, 2018 Category: Endocrinology Authors: Nagareddy, P. R., Noothi, S. K., Flynn, M. C., Murphy, A. J. Tags: Review Source Type: research

The continuous challenge of antithrombotic strategies in diabetes: focus on direct oral anticoagulants
AbstractDirect oral anticoagulants (DOACs) include dabigatran, which inhibits thrombin, and apixaban, edoxaban, and rivaroxaban, which inhibit factor Xa. They have been extensively studied in large trials involving patients affected by the most common cardiovascular diseases. As the presence of diabetes leads to peculiar changes in primary and secondary hemostasis, in this review we highlight the current evidence regarding DOAC use in diabetic patients included in the majority of recently conducted studies. Overall, in trials involving patients with atrial fibrillation, data seem to confirm at least a similar efficacy and ...
Source: Acta Diabetologica - September 23, 2019 Category: Endocrinology Source Type: research

Discontinuing Aspirin After Short Term Use Versus Continuous Use with a P2Y12 Inhibitor for the Treatment of Patients with Type 2 Diabetes Mellitus Following Percutaneous Coronary Intervention: A Meta-analysis
ConclusionDiscontinuing ASA after short-term use for the treatment of patients with T2DM following PCI was not associated with any increased cardiovascular outcomes. Also, discontinuing ASA after short-term use and continuing the use of a P2Y12 inhibitor were somewhat safer in these patients with T2DM. Further research should follow.
Source: Diabetes Therapy - September 23, 2020 Category: Endocrinology Source Type: research

Treatment of the New Era: Long-Term Ticagrelor Monotherapy for the Treatment of Patients with Type 2 Diabetes Mellitus following Percutaneous Coronary Intervention: A Meta-analysis
ConclusionLong-term ticagrelor monotherapy after a short course of DAPT use showed better results in patients with T2DM following PCI. Therefore, ticagrelor monotherapy after a short course of DAPT use could be considered an evolution in antiplatelet therapy of this decade for the treatment of patients with T2DM after PCI. However, newer studies with a larger population size and cost-effectiveness are factors that should further be considered.
Source: Diabetes Therapy - December 9, 2022 Category: Endocrinology Source Type: research

Aspirin in diabetic patients at primary prevention: insights of the VITAL cohort
ConclusionsThe VITAL data confirmed diabetes as an important risk factor for cardiovascular events in a contemporary cohort but did not show cardiovascular benefits of aspirin in primary prevention among people with diabetes who were shown to be at higher risk of cardiovascular events.
Source: Journal of Endocrinological Investigation - January 18, 2023 Category: Endocrinology Source Type: research